NewBiotics
Turning drug resistance into therapeutic breakthroughs, pioneering drug molecules for cancer and infectious diseases since 1997.
Turning drug resistance into therapeutic breakthroughs, pioneering drug molecules for cancer and infectious diseases since 1997.
NewBiotics, a pioneering company in the Health Care industry, has been focusing on turning drug resistance into therapeutic breakthroughs since its establishment in 1997. Their emphasis on the discovery and development of drug molecules that utilize the cycle of drug resistance in both cancer and infectious diseases has garnered attention. Acquired by Celmed Biosciences on June 7, 2004, NewBiotics received a significant $4.57M Series E investment on April 27, 2004. The investment was led by Life Science Partners, AgeChem, and Inglewood Ventures. With their innovative approach and strong financial backing, NewBiotics continues to make strides in the field of therapeutic drug development.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | $4.57M | 3 | Inglewood Ventures, GeneChem +1 | 27 Apr 2004 |
| Series C | $11.00M | 6 |
|
25 Jul 2001 |
| Venture Round | $6.30M | 1 | EQT Life Sciences | 04 Apr 2000 |
No recent news or press coverage available for NewBiotics.
We care about your data, and we'd love to use cookies make your experience better.